Comparing Veracyte (NASDAQ:VCYT) & BeyondSpring (NASDAQ:BYSI)

BeyondSpring (NASDAQ:BYSI) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Volatility and Risk

BeyondSpring has a beta of 0.06, suggesting that its share price is 94% less volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500.

Earnings & Valuation

This table compares BeyondSpring and Veracyte”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75 million	17.07	-$1.01 million	($0.12)	-6.06
Veracyte	$517.15 million	6.81	$66.35 million	$1.41	31.08

Veracyte has higher revenue and earnings than BeyondSpring. BeyondSpring is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for BeyondSpring and Veracyte, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1	0	0	0	1.00
Veracyte	1	2	6	2	2.82

Veracyte has a consensus target price of $55.78, indicating a potential upside of 27.29%. Given Veracyte’s stronger consensus rating and higher probable upside, analysts clearly believe Veracyte is more favorable than BeyondSpring.

Institutional and Insider Ownership

40.3% of BeyondSpring shares are held by institutional investors. 29.3% of BeyondSpring shares are held by company insiders. Comparatively, 1.6% of Veracyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares BeyondSpring and Veracyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-28.88%
Veracyte	20.37%	9.26%	8.61%

Summary

Veracyte beats BeyondSpring on 12 of the 15 factors compared between the two stocks.

About BeyondSpring

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

About Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.